These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 37169665)

  • 1. Discordance between lipoprotein (a) and LDL-cholesterol levels in cardiovascular risk assessment in apparently healthy subjects.
    Bergmann K; Stefanska A; Krintus M; Sypniewska G
    Nutr Metab Cardiovasc Dis; 2023 Jul; 33(7):1429-1436. PubMed ID: 37169665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Elevated Lipoprotein(a) Cncentration and Presence of Subfractions of Small Dense Low Density Lipoproteins as Independent Factors of Risk of Ischemic Heart Disease].
    Afanasieva OI; Utkina EA; Artemieva NV; Ezhov MV; Adamova IY; Pokrovsky SN
    Kardiologiia; 2016 Jun; 56(6):5-11. PubMed ID: 28290840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discordance among apoB, non-high-density lipoprotein cholesterol, and triglycerides: implications for cardiovascular prevention.
    Sniderman AD; Dufresne L; Pencina KM; Bilgic S; Thanassoulis G; Pencina MJ
    Eur Heart J; 2024 Jul; 45(27):2410-2418. PubMed ID: 38700053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipoprotein profiles, not anthropometric measures, correlate with serum lipoprotein(a) values in children: the Taipei children heart study.
    Chu NF; Makowski L; Chang JB; Wang DJ; Liou SH; Shieh SM
    Eur J Epidemiol; 2000 Jan; 16(1):5-12. PubMed ID: 10780336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atherogenic forms of dyslipidaemia in women with polycystic ovary syndrome.
    Berneis K; Rizzo M; Hersberger M; Rini GB; Di Fede G; Pepe I; Spinas GA; Carmina E
    Int J Clin Pract; 2009 Jan; 63(1):56-62. PubMed ID: 19125993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes).
    Albers JJ; Slee A; O'Brien KD; Robinson JG; Kashyap ML; Kwiterovich PO; Xu P; Marcovina SM
    J Am Coll Cardiol; 2013 Oct; 62(17):1575-9. PubMed ID: 23973688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Residual dyslipidemia according to low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B among statin-treated US adults: National Health and Nutrition Examination Survey 2009-2010.
    Wong ND; Chuang J; Zhao Y; Rosenblit PD
    J Clin Lipidol; 2015; 9(4):525-32. PubMed ID: 26228670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concordance/discordance between serum apolipoprotein B, low density lipoprotein cholesterol and non-high density lipoprotein cholesterol in NATPOL 2011 participants - An epidemiological perspective.
    Solnica B; Sniderman AD; Wyszomirski A; Rutkowski M; Chlebus K; Bandosz P; Pencina MJ; Zdrojewski T
    Int J Cardiol; 2023 Nov; 390():131150. PubMed ID: 37429441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study.
    Sharrett AR; Ballantyne CM; Coady SA; Heiss G; Sorlie PD; Catellier D; Patsch W;
    Circulation; 2001 Sep; 104(10):1108-13. PubMed ID: 11535564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Method for estimating high sdLDL-C by measuring triglyceride and apolipoprotein B levels.
    Hayashi T; Koba S; Ito Y; Hirano T
    Lipids Health Dis; 2017 Jan; 16(1):21. PubMed ID: 28125987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Physiological Bases for the Superiority of Apolipoprotein B Over Low-Density Lipoprotein Cholesterol and Non-High-Density Lipoprotein Cholesterol as a Marker of Cardiovascular Risk.
    Glavinovic T; Thanassoulis G; de Graaf J; Couture P; Hegele RA; Sniderman AD
    J Am Heart Assoc; 2022 Oct; 11(20):e025858. PubMed ID: 36216435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gender-specific association of coronary artery calcium and lipoprotein parameters: the Heinz Nixdorf Recall Study.
    Erbel R; Lehmann N; Churzidse S; Möhlenkamp S; Moebus S; Mahabadi AA; Schmermund A; Stang A; Dragano N; Grönemeyer D; Seibel R; Kälsch H; Bauer M; Bröcker-Preuss M; Mann K; Jöckel KH;
    Atherosclerosis; 2013 Aug; 229(2):531-40. PubMed ID: 23701995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meta-analysis of comparison of effectiveness of lowering apolipoprotein B versus low-density lipoprotein cholesterol and nonhigh-density lipoprotein cholesterol for cardiovascular risk reduction in randomized trials.
    Robinson JG; Wang S; Jacobson TA
    Am J Cardiol; 2012 Nov; 110(10):1468-76. PubMed ID: 22906895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Extended-Release Niacin on High-Density Lipoprotein (HDL) Functionality, Lipoprotein Metabolism, and Mediators of Vascular Inflammation in Statin-Treated Patients.
    Yadav R; Liu Y; Kwok S; Hama S; France M; Eatough R; Pemberton P; Schofield J; Siahmansur TJ; Malik R; Ammori BA; Issa B; Younis N; Donn R; Stevens A; Durrington P; Soran H
    J Am Heart Assoc; 2015 Sep; 4(9):e001508. PubMed ID: 26374297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small, dense LDL cholesterol and apolipoprotein B: relationship with serum lipids and LDL size.
    Vekic J; Zeljkovic A; Jelic-Ivanovic Z; Spasojevic-Kalimanovska V; Bogavac-Stanojevic N; Memon L; Spasic S
    Atherosclerosis; 2009 Dec; 207(2):496-501. PubMed ID: 19632678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between high-normal levels of alanine aminotransferase and risk factors for atherogenesis.
    Siddiqui MS; Sterling RK; Luketic VA; Puri P; Stravitz RT; Bouneva I; Boyett S; Fuchs M; Sargeant C; Warnick GR; Grami S; Sanyal AJ
    Gastroenterology; 2013 Dec; 145(6):1271-9.e1-3. PubMed ID: 23973920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipoprotein(a) and risk-weighted apolipoprotein B: a novel metric for atherogenic risk.
    Rehman MB; Tudrej BV
    Lipids Health Dis; 2024 Sep; 23(1):316. PubMed ID: 39334349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Specific Increase in Small Dense Low-Density Lipoprotein-Cholesterol Levels beyond Triglycerides in Patients with Diabetes: Implications for Cardiovascular Risk of MAFLD.
    Hirano T; Satoh N; Ito Y
    J Atheroscler Thromb; 2024 Jan; 31(1):36-47. PubMed ID: 37438123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantifying the contribution of lipoprotein(a) to all apoB containing particles.
    Chilazi M; Zheng W; Park J; Marvel FA; Khoury S; Jones SR; Martin SS
    J Clin Lipidol; 2022; 16(2):220-226. PubMed ID: 35241398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of Genetic Variants Related to CETP Inhibitors and Statins With Lipoprotein Levels and Cardiovascular Risk.
    Ference BA; Kastelein JJP; Ginsberg HN; Chapman MJ; Nicholls SJ; Ray KK; Packard CJ; Laufs U; Brook RD; Oliver-Williams C; Butterworth AS; Danesh J; Smith GD; Catapano AL; Sabatine MS
    JAMA; 2017 Sep; 318(10):947-956. PubMed ID: 28846118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.